- Home
- WCT vs ADVM Comparison
WCT vs ADVM Comparison
Compare WCT & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- ADVM
- Stock Information
- Founded
- WCT 2012
- ADVM 2006
- Country
- WCT Hong Kong
- ADVM United States
- Employees
- WCT N/A
- ADVM N/A
- Industry
- WCT
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WCT
- ADVM Health Care
- Exchange
- WCT NYSE
- ADVM Nasdaq
- Market Cap
- WCT 100.9M
- ADVM 119.6M
- IPO Year
- WCT 2024
- ADVM 2014
- Fundamental
- Price
- WCT $2.42
- ADVM $3.94
- Analyst Decision
- WCT
- ADVM Strong Buy
- Analyst Count
- WCT 0
- ADVM 6
- Target Price
- WCT N/A
- ADVM $27.83
- AVG Volume (30 Days)
- WCT 3.7M
- ADVM 149.4K
- Earning Date
- WCT 12-07-2024
- ADVM 03-17-2025
- Dividend Yield
- WCT N/A
- ADVM N/A
- EPS Growth
- WCT N/A
- ADVM N/A
- EPS
- WCT 0.05
- ADVM N/A
- Revenue
- WCT $2,370,163.00
- ADVM $1,000,000.00
- Revenue This Year
- WCT N/A
- ADVM N/A
- Revenue Next Year
- WCT N/A
- ADVM $1,342.84
- P/E Ratio
- WCT $52.43
- ADVM N/A
- Revenue Growth
- WCT N/A
- ADVM N/A
- 52 Week Low
- WCT $0.94
- ADVM $3.85
- 52 Week High
- WCT $9.36
- ADVM $22.30
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- ADVM 38.74
- Support Level
- WCT N/A
- ADVM $3.85
- Resistance Level
- WCT N/A
- ADVM $4.63
- Average True Range (ATR)
- WCT 0.00
- ADVM 0.30
- MACD
- WCT 0.00
- ADVM -0.01
- Stochastic Oscillator
- WCT 0.00
- ADVM 8.76
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.